The present invention relates to the fields of life sciences and medicine. Specifically the invention relates to cancer therapies of humans. More specifically the present invention relates to oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect the present invention relates to separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore the present invention relates to a pharmaceutical kit and a pharmaceutical composition both utilizing oncolytic adenoviral vectors.
